Publications
Search our bibliography using the filters on the right-hand side.
Displaying 351 through 400 of 695 publications.
Skip to main content
Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.
Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.
Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355
Lewis S, Price M, Dwyer KA, O'Brien S, Heekin RD, Yates PJ, Beverland D, Mordin M. Development of a scale to assess performance following primary total knee arthroplasty. Value Health. 2014 Apr 21;17(4):350-9. doi: 10.1016/j.jval.2014.01.006
Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295
Davis A, Mehrotra S, Holl J, Daskin MS. Nurse staffing under demand uncertainty to reduce costs and enhance patient safety. Asia Pac J Oper. 2014 Feb;31(1):1-19. doi: 10.1142/S0217595914500055
Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Graham CN, Knox HN, Winfree KB, Hess LM, Liu J, Ortuzar WF. Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC). Poster presented at the Quality Care Symposium of the American Society of Clinical Oncology; November 2013.
Duruöz MT, Doward L, Turan Y, Cerrahoglu L, Yurtkuran M, Calis M, Tas N, Ozgocmen S, Yoleri O, Durmaz B, Oncel S, Tuncer T, Sendur O, Birtane M, Tuzun F, Bingol U, Kirnap M, Celik Erturk G, Ardicoglu O, Memis A, Atamaz F, Kizil R, Kacar C, Gurer G, Uzunca K, Sari H. Translation and validation of the Turkish version of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. Rheumatol Int. 2013 Nov;33(11):2717-22. doi: 10.1007/s00296-013-2796-y.
Brennan VK, Talbird SE, Beard SM, Brogan AJ, Flanagan D, Delpech V, Bosanquet N, Fisher M. The public health and economic impact from earlier diagnosis and earlier antiretroviral treatment of HIV in the UK. Poster presented at the 14th European AIDS Conference/EACS; October 16, 2013.
Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Odom DM, Talbird SE, Brogan AJ, Schenkel B. A meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the Summer Meeting of the American Academy of Dermatology; August 2013.
Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.
Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013 Aug 1;3(8):e003028.
Brown TM, Holland J, Bokowy KL, Horblyuk R. Can transformational programs aimed at improving hospital management, leadership, and productivity systems affect financial performance? J Hospital Admin. 2013 Jul 30;2(4):111-9.
Wood WA, Whitley J, Goyal RK, Brown PM, Sharf A, Irons R, Rao KV, Essenmacher A, Serody JS, Coghill JM, Armistead PM, Sarantopoulos S, Gabriel DA, Shea TC. Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. Bone Marrow Transplant. 2013 Jun;48(6):771-6. doi: 10.1038/bmt.2012.216
Davis AE, Mehrotra S, Friedewald J, Ladner D. Predicting long run geographic disparities in kidney transplantation via fluid approximations. Poster presented at the Institute for Operations Research and Management Science (INFORMS) Healthcare Conference; June 2013.
Davis KL, Mody R, Rubin DT, Wang E. Association between suboptimal therapy and health care costs in inflammatory bowel disease. Poster presented at the 2013 Digestive Disease Week; May 2013.
Herring WL, Mladsi D, Mauskopf J. Patient-level simulation modeling for economic evaluations: opportunities and challenges in a practical setting. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 1, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A28-9.
Herring WL, Mladsi DM, Miles L, Ronquest N. A novel approach to ranking parameter uncertainty in one-way sensitivity analysis: what tornado diagrams are missing. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 1, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A20.
Ronquest N, Mladsi D, Hopley C, Edgell E. The economic value of an innovative knee implant system for total knee arthroplasty. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 6, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A225.
Davis AE, Mehrotra S, McElroy L. Implications of statewide sharing on geographic disparity in kidney transplantation in the US. Poster presented at the American Transplant Congress; May 2013.
Schenck A, Meyer A-M, Carpenter WR, Cilenti D, Kuo M, Goyal RK. Assessing public health return on investment: using the NACCHO profile data. Poster presented at the National Network of Public Health Institutes; May 2013.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Perez-Gutthann S. Post-approval safety studies: impact of 2012 pv legislation & guidance. Poster presented at the DIA 7th European Forum for Qualified Person for Pharmacovigilance (QPPV); April 19, 2013.
Fehnel SE. Choice of recall period in patient-reported outcome measurement. Presented at the 4th Annual Patient-Reported Outcome Consortium Workshop; April 1, 2013.
Stull DE, Houghton K. Identifying differential responders and their characteristics in clinical trials: innovative methods for analyzing longitudinal data. Value Health. 2013 Jan 1;16(1):164-76.
Mauskopf J, Chirila C, Masaquel C, Boye KS, Bowman L, Birt J, Grainger D. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013 Jan 1;29(1):92-100.
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Karve SJ, Price GL, Davis KL, Pohl G, Walgren RA. Health care utilization and associated costs in elderly persons with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):4273. doi: 10.1182/blood.V120.21.4273.4273
Cohen C, Davis KL, Meyers JL. Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. Poster presented at the 11th International Congress on Drug Therapy in HIV Infection; November 2012.
Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.
Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Assessing impacts of major depressive disorder on depression. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 1, 2012. Berlin, Germany.
Davis AE, Mehrotra S, Friedewald J. Improving utilization and outcomes of high kidney donor profile index kidney transplants. Poster presented at the Annual Meeting ofthe Institute for Operations Research and Management Science; October 2012. Previously presented at the 2010 American Transplant Congress.
Cilenti D, Wells R, Kum HC, Domino M, Goyal RK, Hillemeier M. How NC maternal and child health services and outcomes changed during a period of revenue cuts. Poster presented at the NC Public Health Association Conference; September 2012.
Ferguson JE3rd, Goyal RK, Raynor MC, Nielsen ME, Pruthi RS, Brown PM, Wallen EM. Cost analysis of robot-assisted laparoscopic versus hand-assisted laparoscopic partial nephrectomy. J Endourol. 2012 Aug;26(8):1030-7.
Mauskopf JA, Candrilli SD, Chevrou-Severac H, Ochoa JB. Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. World J Surg Oncol. 2012 Jul 1;10:136.
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Lewis S, Price M, Mordin M, Dwyer K, Heekin R, Yates P, O'Brien S, Beverland D. Assessing performance following primary total knee arthroplasty: development of the patient's knee implant performance (PKIP) measure. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. [abstract] Value Health. 2012 Jun 1; 15(4):A70.
Petrillo J, Cano S, McLeod LD, Coon CD. What is the value of classical test theory, item response theory, and Rasch measurement theory in the development of patient-reported outcome instruments? Presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC.
Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.
Mladsi DM, Graham JB, Ronquest NA. Trade-off analysis: an extension of threshold pricing analysis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A169.
Mladsi D, Herring WL, Earnshaw S. Cost-effectiveness analysis in personalized medicine: general hypotheses and corresponding decision tree structures for screening, diagnostic, predictive, prognostic, surveillance, and monitoring tests. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A168-9.
Karve SJ, Price G, Davis KL, Pohl G, Smith EN. Comparison of treatment patterns, health care utilization, and direct costs in elderly patients with distant-stage small cell lung cancer (SCLC) versus non-small cell lung cancer (NSCLC) using the SEER-medicare database. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 2012.
Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early parkinson disease therapies. Am J Manag Care. 2012 May 1;4(3):99-107.
Mladsi D, Curtis S, Bell MJ, Ito T, Wilson M, Aboud M. Resource utilisation and cost of managing adverse events (AEs) associated with highly active antiretroviral therapy (HAART) in patients with HIV-1. Poster presented at the 18th Annual Conference of the British HIV Association; April 1, 2012. Birmingham, UK. [abstract] HIV Med. 2012 Apr 18; 13(SI):17-8.